1. Home
  2. SWTX vs WEN Comparison

SWTX vs WEN Comparison

Compare SWTX & WEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWTX
  • WEN
  • Stock Information
  • Founded
  • SWTX 2017
  • WEN 1969
  • Country
  • SWTX United States
  • WEN United States
  • Employees
  • SWTX N/A
  • WEN N/A
  • Industry
  • SWTX Biotechnology: Pharmaceutical Preparations
  • WEN Restaurants
  • Sector
  • SWTX Health Care
  • WEN Consumer Discretionary
  • Exchange
  • SWTX Nasdaq
  • WEN Nasdaq
  • Market Cap
  • SWTX 3.0B
  • WEN 3.1B
  • IPO Year
  • SWTX 2019
  • WEN N/A
  • Fundamental
  • Price
  • SWTX $37.92
  • WEN $12.68
  • Analyst Decision
  • SWTX Strong Buy
  • WEN Hold
  • Analyst Count
  • SWTX 5
  • WEN 19
  • Target Price
  • SWTX $72.40
  • WEN $18.39
  • AVG Volume (30 Days)
  • SWTX 2.2M
  • WEN 5.6M
  • Earning Date
  • SWTX 05-01-2025
  • WEN 05-02-2025
  • Dividend Yield
  • SWTX N/A
  • WEN 7.89%
  • EPS Growth
  • SWTX N/A
  • WEN N/A
  • EPS
  • SWTX N/A
  • WEN 0.95
  • Revenue
  • SWTX $191,589,000.00
  • WEN $2,246,492,000.00
  • Revenue This Year
  • SWTX $85.98
  • WEN $1.36
  • Revenue Next Year
  • SWTX $69.16
  • WEN $4.26
  • P/E Ratio
  • SWTX N/A
  • WEN $13.35
  • Revenue Growth
  • SWTX 3417.33
  • WEN 2.98
  • 52 Week Low
  • SWTX $28.21
  • WEN $12.05
  • 52 Week High
  • SWTX $62.00
  • WEN $20.65
  • Technical
  • Relative Strength Index (RSI)
  • SWTX 39.33
  • WEN 34.30
  • Support Level
  • SWTX $36.08
  • WEN $12.40
  • Resistance Level
  • SWTX $38.77
  • WEN $13.44
  • Average True Range (ATR)
  • SWTX 3.21
  • WEN 0.61
  • MACD
  • SWTX -0.17
  • WEN -0.09
  • Stochastic Oscillator
  • SWTX 36.05
  • WEN 22.34

About SWTX SpringWorks Therapeutics Inc.

SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.

About WEN Wendy's Company (The)

The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $12.3 billion in 2023, narrowly edging Burger King ($11.5 billion) and clocking in well behind wide-moat McDonald's ($53.1 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spanned almost 7,157 total stores in 30 countries as of year-end 2023. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.

Share on Social Networks: